Seres Therapeutics (MCRB) Misses Q2 EPS by 24c

Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($0.70), $0.24 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $3 million versus the consensus estimate of $4.2 million.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• SolarEdge (SEDG) PT Lowered to $31 at Jefferies, 'We see shares as an unappealing short, not a compelling long'
• Deutsche Bank cuts Novo Nordisk to Sell after earnings, shares dip
• Dollar Tree (DLTR) Tops Q2 EPS by $1.59, Beats on Revenue; Offers FY Guidance